THYROID ANTIBODIES AS A RISK FACTOR FOR TRISOMY BIRTHS

有大量的流行病学证据表明， 患有唐氏综合症或其他三体的儿童的出生 血清中甲状腺抗体的存在， 孩子的父母。 此类研究的案例选自 患有综合征的儿童或成人， 生命的最初几年。 如果甲状腺抗体是 染色体不分离，那么这些抗体应该是 在怀孕时存在于父母中;否则， 相关性可能是由于幸存者的选择偏差， 改变免疫系统可以起到保护作用 我们将检验甲状腺抗体与 在一项病例对照研究中，所有病例和 在出生时确定对照， 在怀孕开始时抽取并储存以备将来使用 research. 115例病例已从两个 大型纵向研究，儿童健康和发展 研究（CHDS）和围产期合作项目（CPP）， 分别为20，000和50，000例。 每台三个控制器 将从相同人群中选择病例，并匹配 父亲和母亲的年龄和种族。 父母的血清将 做了甲状腺抗体检测 如果这种联系得到证实，它可能会有重要的公众 健康影响，因为目前还没有已知的风险 年龄以外的其他因素，以确定母亲是否有可能 一个三体性的孩子 虽然DS的发病率是 在35至45岁的女性中，大多数DS 出生于年轻的母亲，作为一个群体， 不会是成本效益或风险效益。 甲状腺抗体测试 价格便宜，对母子双方没有风险。 母亲 然后可以通过其他方法进行测试， 子宫穿刺术。 这项研究设计提供了独特的机会， 以最低的成本测试这一重要假设，因为 所需的记录和血液已经可供分析。

There is a body of epidemiologic evidence that has associated the birth of children with Down's syndrome or with other trisomies with the presence of thyroid antibodies in the serum of those children's parents. Cases for such studies were selected from children or adults with the syndromes who had survived the earliest years of life. If thyroid antibodies are a risk factor for chromosomal non-disjunction, then those antibodies should be present in a parent at the time of conception; otherwise the association could be due to selection bias for survivors whose altered immune system could be protective. We will test the hypothesis of an association of thyroid antibodies with trisomy births in a case-control study in which all cases and controls were ascertained at birth and all parental sera were drawn at the beginning of the pregnancy and stored for future research. 115 cases have been identified from the records of two large longitudinal studies, the Child Health and Development Study (CHDS) and the Collaborative Perinatal Project (CPP), with some 20,000 and 50,000 births respectively. Three controls per case will be selected from the same populations and matched for age and race of the mother and the father. Parental sera will be tested for thyroid antibodies. If this association is verified, it could have important public health implications because, at this time, there are no known risk factors other than age for the identification of mothers at risk of a trisomy birth. Although the incidence of DS is 10 to 100 times greater in women 35 to 45 years of age, the majority of DS are born to younger mothers for whom, as a group, amniocentesis would not be cost or risk effective. A test for thyroid antibodies is inexpensive and without risk to the mother-child pair. Mothers who were positive could then be tested by other means such as amniocentesis. This study design offers the unique opportunity to test this important hypothesis at a minimum of cost because the needed records and bloods are already available for analysis.